KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Non-Current Debt (2018 - 2021)

TherapeuticsMD's Non-Current Debt history spans 6 years, with the latest figure at $171.7 million for Q3 2021.

  • For Q3 2021, Non-Current Debt fell 27.55% year-over-year to $171.7 million; the TTM value through Sep 2021 reached $171.7 million, down 27.55%, while the annual FY2020 figure was $237.7 million, 22.13% up from the prior year.
  • Non-Current Debt reached $171.7 million in Q3 2021 per TXMD's latest filing, down from $175.3 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $243.8 million in Q2 2020 to a low of $73.1 million in Q2 2018.
  • Average Non-Current Debt over 4 years is $168.9 million, with a median of $186.5 million recorded in 2019.
  • Peak YoY movement for Non-Current Debt: surged 231.19% in 2020, then fell 28.11% in 2021.
  • A 4-year view of Non-Current Debt shows it stood at $73.4 million in 2018, then surged by 165.24% to $194.6 million in 2019, then rose by 22.13% to $237.7 million in 2020, then fell by 27.75% to $171.7 million in 2021.
  • Per Business Quant, the three most recent readings for TXMD's Non-Current Debt are $171.7 million (Q3 2021), $175.3 million (Q2 2021), and $179.0 million (Q1 2021).